- Home
- / Therapix Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Therapix Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.4
2021-01-28
Market Capitalization
$4.5 M
2021-01-28
Revenue
$856 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 12, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3M | 2.9M | 1.3M | 856.0K | ||||
| Cost of goods sold | 322.0K | 683.0K | 800.0K | 225.0K | ||||
| Gross profit | 1.0M | 2.2M | 506.0K | 631.0K | ||||
| Gross profit margin, % | 76.1% | 76.3% | 38.7% | 73.7% | ||||
| Operating expense total | 9.2M | 4.0M | 2.5M | 5.8M | 9.2M | 7.4M | 7.3M | 9.1M |
| Depreciation and amortization | 546.0K | 122.0K | 7.0K | 12.0K | 148.0K | 1.6M | 1.7M | 350.0K |
| EBITDA | (9.2M) | (4.0M) | (2.5M) | (5.8M) | (8.2M) | (5.4M) | (7.3M) | (6.8M) |
| EBITDA margin, % | -612.3% | -189.1% | -556.5% | -792.4% | ||||
| EBIT | (9.2M) | (4.3M) | (2.6M) | (5.8M) | (8.4M) | (7.0M) | (9.0M) | (6.6M) |
| EBIT margin, % | -623.3% | -244.0% | -690.3% | -776.1% | ||||
| Interest income | 35.0K | 11.0K | 421.0K | 207.0K | ||||
| Interest expense | 123.0K | 676.0K | 860.0K | 18.0K | 1.2M | 9.0K | 30.0K | 421.0K |
| Pre tax profit | (9.0M) | (4.7M) | (3.5M) | (5.8M) | (2.6M) | (5.9M) | (7.5M) | (12.6M) |
| Income tax expense | (60.0K) | 14.0K | 22.0K | (14.0K) | ||||
| Net Income | (8.9M) | (4.7M) | (3.5M) | (5.8M) | (2.6M) | (5.9M) | (7.5M) | (12.6M) |